Vernalis, Roche in new obesity deal

Vernalis (LSE:VER) and Roche (SWX:ROCZ) signed a new obesity deal covering the development of 5-HT(2C) receptor antagonists as appetite suppressants. Under the new deal, ROCZ will pay VER research funding, preclinical milestones and royalties in exchange for worldwide development and marketing rights to 5-HT(2C) product candidates. The first compound is expected to enter Phase I trials soon, according to the partners. ...